Table 2. Multivariable-adjusted associations of insulin resistance with serum lipids and neutrophil count.
| Population Explanatory variable | HOMA-IR | Insulin index | ||
|---|---|---|---|---|
| Estimate (95% CI) | p | Estimate (95% CI) | p | |
| Lu He patients | ||||
| Triglycerides (+1.15 mmol/L) | 11.7 (6.8 to 16.9) | <0.0001 | 8.0 (3.4 to 12.9) | 0.0006 |
| HDL-cholesterol (+0.28 mmol/L) | -11.2 (-15.1 to -7.1) | <0.0001 | -8.6 (-12.5 to -4.5) | <0.0001 |
| Neutrophils (1.41 × 109/L) | 5.8 (1.0 to 10.7) | 0.017 | 5.6 (1.1 to 10.4) | 0.0151 |
| FLEMENGHO participants | ||||
| Triglycerides (+0.88 mmol/L) | 12.8 (9.4 to 15.8) | <0.0001 | 12.4 (9.3 to 15.7) | <0.0001 |
| HDL-cholesterol (+0.38 mmol/L) | -6.0 (-8.7 to -3.3) | <0.0001 | -5.8 (-8.5 to -3.1) | <0.0001 |
| Neutrophils (1.21 × 109/L) | 3.8 (0.9 to 6.9) | 0.0112 | 4.0 (1.1 to 7.1) | 0.0074 |
Insulin index refers to C-peptide in Lu He patients and insulin in FLEMENGHO participants. Estimates express the percentage change in the dependent variable associated with a 1-SD increment in the explanatory variables. All estimates were standardised to the average in each population (mean or ratio) of age, body mass index, mean arterial pressure, and use of antidiabetic medications (by class), lipid-lowering drugs (by class), antihypertensive drugs (by class), and nonsteroidal anti-inflammatory drugs (see S3 Table). Each explanatory variable was entered separately in the models.